Reported 2 days ago
Pfizer Inc. (NYSE:PFE) announced its Q2 2025 financial results, reporting revenues of $14.7 billion, up 10% from the same quarter last year, alongside an increase in adjusted diluted EPS guidance to between $2.90 and $3.10. The growth was driven by strong sales in products like Vyndaqel, Comirnaty, and Paxlovid, despite challenges from increased manufacturer discounts due to Medicare reforms.
Source: YAHOO